Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 27, Issue 11, Pages 2004-2016
Publisher
Oxford University Press (OUP)
Online
2016-08-09
DOI
10.1093/annonc/mdw321
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer
- (2017) Xin Nie et al. Cancer Biomarkers
- Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
- (2016) Joseph Ciccolini et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Problems of variable biomarker evaluation in stratified medicine research—A case study of ERCC1 in non-small-cell lung cancer
- (2016) Kinga Malottki et al. LUNG CANCER
- European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?
- (2015) M. Malvezzi et al. ANNALS OF ONCOLOGY
- Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents
- (2015) Takehito Shukuya et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- TIF1 Suppresses Tumor Progression by Regulating Mitotic Checkpoints and Chromosomal Stability
- (2015) R. M. Pommier et al. CANCER RESEARCH
- Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer
- (2015) Roland Hubaux et al. INTERNATIONAL JOURNAL OF CANCER
- AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells
- (2015) Stuti Agarwal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Predicting Anthracycline Benefit:TOP2Aand CEP17—Not Only but Also
- (2015) John M.S. Bartlett et al. JOURNAL OF CLINICAL ONCOLOGY
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in NSCLC: latest evidence and clinical potential
- (2015) Raghav Sundar et al. Therapeutic Advances in Medical Oncology
- Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches
- (2015) Meghan Shea et al. Therapeutic Advances in Respiratory Disease
- TIMP-1 Inhibits Apoptosis in Lung Adenocarcinoma Cells via Interaction with Bcl-2
- (2015) Srilatha Nalluri et al. PLoS One
- Topoisomerase-I PS506 as a Dual Function Cancer Biomarker
- (2015) Ming Zhao et al. PLoS One
- Biodiversity on the Rocks: Macrofauna Inhabiting Authigenic Carbonate at Costa Rica Methane Seeps
- (2015) Lisa A. Levin et al. PLoS One
- Hedgehog Pathway Inhibitor HhAntag691 Is a Potent Inhibitor of ABCG2/BCRP and ABCB1/Pgp
- (2015) Yimao Zhang et al. NEOPLASIA
- HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics
- (2014) Peter A. Fasching et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)
- (2014) Gerold Bepler et al. CANCER
- Transport properties of pancreatic cancer describe gemcitabine delivery and response
- (2014) Eugene J. Koay et al. JOURNAL OF CLINICAL INVESTIGATION
- Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC
- (2014) Stéphane Champiat et al. Journal of Thoracic Oncology
- Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer
- (2014) Eric S. Kim et al. LUNG CANCER
- Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types
- (2014) Ronald Lebofsky et al. Molecular Oncology
- Topoisomerase IIα in chromosome instability and personalized cancer therapy
- (2014) T Chen et al. ONCOGENE
- Response to First-Line Chemotherapy in Patients with Non-Small Cell Lung Cancer According to RRM1 Expression
- (2014) Xiaopeng Dong et al. PLoS One
- The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis
- (2014) Yanlong Yang et al. TUMOR BIOLOGY
- Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer
- (2014) R C Turkington et al. Cell Death & Disease
- Update on the Methods of the U.S. Preventive Services Task Force: Insufficient Evidence
- (2013) Diana B. Petitti ANNALS OF INTERNAL MEDICINE
- Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis
- (2013) Yu Liu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Erlotinib, Gefitinib, and Vandetanib Inhibit Human Nucleoside Transporters and Protect Cancer Cells from Gemcitabine Cytotoxicity
- (2013) V. L. Damaraju et al. CLINICAL CANCER RESEARCH
- Randomized International Phase III Trial of ERCC1 and RRM1 Expression–Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non–Small-Cell Lung Cancer
- (2013) Gerold Bepler et al. JOURNAL OF CLINICAL ONCOLOGY
- ERCC1 and RRM1: Ready for Prime Time?
- (2013) Benjamin Besse et al. JOURNAL OF CLINICAL ONCOLOGY
- Silencing of X-Linked Inhibitor of Apoptosis Decreases Resistance to Cisplatin and Paclitaxel but Not Gemcitabine in Non-Small Cell Lung Cancer
- (2013) Y Liu et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer
- (2013) Francesca Mazzoni et al. LUNG CANCER
- CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells
- (2013) Svetlana Grabauskiene et al. LUNG CANCER
- Synergistic Anticancer Activity of Arsenic Trioxide with Erlotinib Is Based on Inhibition of EGFR-Mediated DNA Double-Strand Break Repair
- (2013) K. Kryeziu et al. MOLECULAR CANCER THERAPEUTICS
- ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
- (2013) Luc Friboulet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association between TYMS Expression and Efficacy of Pemetrexed–Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
- (2013) Ting Wang et al. PLoS One
- Nucleosome Dynamics as Modular Systems that Integrate DNA Damage and Repair
- (2013) C. L. Peterson et al. Cold Spring Harbor Perspectives in Biology
- Chromosome instability and benefit from adjuvant anthracyclines in breast cancer
- (2012) A F Munro et al. BRITISH JOURNAL OF CANCER
- Impact of biomarker usage on oncology drug development
- (2012) K. Hayashi et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer
- (2012) Ha Yeon Lee et al. LUNG CANCER
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- The potential of exploiting DNA-repair defects for optimizing lung cancer treatment
- (2012) Sophie Postel-Vinay et al. Nature Reviews Clinical Oncology
- Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer
- (2012) I Paul et al. Cell Death & Disease
- Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials
- (2011) T. Reiman et al. ANNALS OF ONCOLOGY
- Optimizing Pemetrexed-Gemcitabine Combination in Patients with Advanced Non-small Cell Lung Cancer: A Pharmacogenetic Approach
- (2011) Tommaso M. De Pas et al. Journal of Thoracic Oncology
- Integrating pharmacogenetics into gemcitabine dosing—time for a change?
- (2011) Joseph Ciccolini et al. Nature Reviews Clinical Oncology
- Phase II failures: 2008–2010
- (2011) John Arrowsmith NATURE REVIEWS DRUG DISCOVERY
- Phase III and submission failures: 2007–2010
- (2011) John Arrowsmith NATURE REVIEWS DRUG DISCOVERY
- All tangled up: how cells direct, manage and exploit topoisomerase function
- (2011) Seychelle M. Vos et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Structural modification of DNA—a therapeutic option in SLE?
- (2011) Steffen Frese et al. Nature Reviews Rheumatology
- Pemetrexed Indirectly Activates the Metabolic Kinase AMPK in Human Carcinomas
- (2010) S. B. Rothbart et al. CANCER RESEARCH
- Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer
- (2010) David J. Stewart CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy
- (2010) Yan Shi et al. TUMOR BIOLOGY
- Class III β-tubulin expression and in vitro resistance to microtubule targeting agents
- (2009) C Stengel et al. BRITISH JOURNAL OF CANCER
- Therapeutics by Cytotoxic Metabolite Accumulation: Pemetrexed Causes ZMP Accumulation, AMPK Activation, and Mammalian Target of Rapamycin Inhibition
- (2009) Alexandra C. Racanelli et al. CANCER RESEARCH
- Resistance to Chemotherapy Is Associated with Fibroblast Growth Factor Receptor 4 Up-Regulation
- (2009) A. Roidl et al. CLINICAL CANCER RESEARCH
- How do anti-mitotic drugs kill cancer cells?
- (2009) K. E. Gascoigne et al. JOURNAL OF CELL SCIENCE
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients
- (2009) Zuleyha Calikusu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy
- (2009) Seong Hyun Jeong et al. LUNG CANCER
- The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
- (2009) G. Scagliotti et al. ONCOLOGIST
- Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
- (2008) J Souglakos et al. BRITISH JOURNAL OF CANCER
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Efficacy and Predictive Molecular Markers of Neoadjuvant Gemcitabine and Pemetrexed in Resectable Non-small Cell Lung Cancer
- (2008) Gerold Bepler et al. Journal of Thoracic Oncology
- Expression of excision repair cross-complementation group 1 and class III β-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer
- (2008) Katsuhiro Okuda et al. LUNG CANCER
- Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells
- (2008) J.-C. Ko et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started